Healthier Future Initiatives for the Eastern Mediterranean Region

By Melike Belenli Gümüş

October 30, 2024

A recent article from the World Health Organization’s Eastern Mediterranean Regional Office (EMRO) highlights three flagship initiatives aimed at achieving a healthier future for the region. These initiatives are essential for expanding equitable access to medical products, improving health workforce resilience, and addressing substance use issues.

Expanding Equitable Access to Medical Products

This initiative aims to improve access to quality medical products, which is essential for closing the healthcare access gap in the Eastern Mediterranean Region. The primary strategies involve developing a new regional pooled procurement mechanism to enhance accessibility and boost countries’ bargaining power with manufacturers. Furthermore, the initiative provides ongoing technical support at the national level to strengthen domestic capacities for the production, distribution, and regulation of medical products.

Investing in a Resilient and Sustainable Health Workforce

The health workforce is the backbone of every effective health system. However, the initiative addresses a severe shortage of health professionals in the region, which is projected to face a shortfall of 2.1 million doctors, nurses, and midwives. Therefore, the initiative focuses on several key aspects to strengthen the health workforce. Investing in health workers is essential for increasing life expectancy, creating jobs, and supporting economic and social development. The initiative also promotes equitable occupational opportunities and aims to protect health professionals from harm. Ultimately, the goal is to build a resilient, fit-for-purpose, and sustainable health workforce across the region, achieving health security by 2030.

Accelerating Public Health Action on Substance Use

Substance use is a significant and growing public health challenge in the region, and this initiative seeks to tackle it by reducing the economic, social, and health burdens associated with substance use disorders. It addresses the alarming 137% increase in drug use disorders over the past 30 years. The initiative aims to ensure that more people receive the necessary treatment, as currently only 1 in 13 people in the region receive treatment compared to 1 in 5 globally. To achieve these goals, the initiative plans to implement strategic region-wide actions and collaborate with other United Nations agencies and partners, as well as provide country-specific interventions and support.

Overall Vision and Objectives

The WHO Regional Director for the Eastern Mediterranean, Dr. Hanan Balkhy, emphasises that these flagship initiatives are part of an ambitious vision to ensure the best attainable level of health for everyone. Expanding equitable access to medical products is a core aspect of this vision. The initiatives align with the WHO’s Fourteenth General Programme of Work and aim to accelerate progress toward achieving the health-related Sustainable Development Goals (SDGs) by 2030. By focusing on these initiatives, the region can make significant strides toward a healthier future for all.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.